KPC PharmaceuticalsInc Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

KPC PharmaceuticalsInc wird ein jährliches Gewinn- und Umsatzwachstum von 28.1% bzw. 13.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 27.9% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 12.1% betragen.

Wichtige Informationen

28.1%

Wachstumsrate der Gewinne

27.9%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	18.7%
Wachstumsrate der Einnahmen	13.8%
Zukünftige Eigenkapitalrendite	12.1%
Analystenabdeckung	Good
Zuletzt aktualisiert	22 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Investors Holding Back On KPC Pharmaceuticals,Inc. (SHSE:600422)

Nov 18

Is KPC Pharmaceuticals,Inc. (SHSE:600422) Trading At A 42% Discount?

Sep 30

These 4 Measures Indicate That KPC PharmaceuticalsInc (SHSE:600422) Is Using Debt Safely

Sep 11

KPC PharmaceuticalsInc (SHSE:600422) Will Pay A Larger Dividend Than Last Year At CN¥0.20

Jul 25

Investors Still Waiting For A Pull Back In KPC Pharmaceuticals,Inc (SHSE:600422)

Jun 25

We Think KPC PharmaceuticalsInc (SHSE:600422) Can Stay On Top Of Its Debt

Jun 04

KPC PharmaceuticalsInc's (SHSE:600422) Profits May Not Reveal Underlying Issues

Mar 28

Gewinn- und Umsatzwachstumsprognosen

SHSE:600422 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CNY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	10,346	863	168	773	6
12/31/2025	9,495	721	279	646	7
12/31/2024	8,187	542	-33	726	6
9/30/2024	7,550	446	557	609	N/A
6/30/2024	7,487	451	725	780	N/A
3/31/2024	7,646	432	752	811	N/A
12/31/2023	7,703	445	291	356	N/A
9/30/2023	7,700	397	261	333	N/A
6/30/2023	7,825	390	141	222	N/A
3/31/2023	7,828	400	-51	38	N/A
12/31/2022	8,282	383	152	254	N/A
9/30/2022	8,419	446	177	296	N/A
6/30/2022	8,388	392	-23	143	N/A
3/31/2022	8,722	427	-33	177	N/A
12/31/2021	8,254	508	15	252	N/A
9/30/2021	8,321	540	-136	93	N/A
6/30/2021	8,386	564	-22	190	N/A
3/31/2021	8,045	560	-79	118	N/A
1/1/2021	7,717	457	251	410	N/A
9/30/2020	7,779	445	128	361	N/A
6/30/2020	7,788	444	104	393	N/A
3/31/2020	7,910	443	292	564	N/A
12/31/2019	8,120	454	82	430	N/A
9/30/2019	7,817	429	145	452	N/A
6/30/2019	7,473	390	131	376	N/A
3/31/2019	7,237	356	146	402	N/A
12/31/2018	7,102	336	135	352	N/A
9/30/2018	6,797	316	362	568	N/A
6/30/2018	6,507	295	N/A	396	N/A
3/31/2018	6,280	318	N/A	197	N/A
12/31/2017	5,852	330	N/A	283	N/A
9/30/2017	5,637	357	N/A	-5	N/A
6/30/2017	5,330	374	N/A	165	N/A
3/31/2017	5,170	416	N/A	179	N/A
12/31/2016	5,101	407	N/A	311	N/A
9/30/2016	5,161	440	N/A	326	N/A
6/30/2016	5,227	448	N/A	378	N/A
3/31/2016	5,049	433	N/A	491	N/A
12/31/2015	4,916	421	N/A	477	N/A
9/30/2015	4,588	404	N/A	485	N/A
6/30/2015	4,456	367	N/A	391	N/A
3/31/2015	4,361	308	N/A	447	N/A
12/31/2014	4,316	289	N/A	404	N/A
9/30/2014	4,038	264	N/A	338	N/A
6/30/2014	3,860	258	N/A	467	N/A
3/31/2014	3,668	243	N/A	325	N/A
12/31/2013	3,584	232	N/A	242	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 600422Das prognostizierte Gewinnwachstum (28.1% pro Jahr) liegt über der Sparquote (2.8%).

Ertrag vs. Markt: 600422Die Erträge des Unternehmens (28.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt CN (26.1% pro Jahr).

Hohe Wachstumserträge: 600422Es wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: 600422Die Einnahmen des Unternehmens (13.8% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt CN (13.8% pro Jahr).

Hohe Wachstumseinnahmen: 600422Die Einnahmen des Unternehmens (13.8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 600422Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (12.1%).

KPC PharmaceuticalsInc Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 7.1% to CN¥25.01

Recent updates

Investors Holding Back On KPC Pharmaceuticals,Inc. (SHSE:600422)

Third quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.22 in 3Q 2023)

KPC Pharmaceuticals,Inc. to Report Q3, 2024 Results on Oct 26, 2024

Is KPC Pharmaceuticals,Inc. (SHSE:600422) Trading At A 42% Discount?

Investor sentiment improves as stock rises 20%

New minor risk - Earnings quality

These 4 Measures Indicate That KPC PharmaceuticalsInc (SHSE:600422) Is Using Debt Safely

Second quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.12 in 2Q 2023)

Investor sentiment deteriorates as stock falls 16%

KPC PharmaceuticalsInc (SHSE:600422) Will Pay A Larger Dividend Than Last Year At CN¥0.20

Dividend increased to CN¥0.20

KPC Pharmaceuticals,Inc. to Report First Half, 2024 Results on Aug 23, 2024

Investors Still Waiting For A Pull Back In KPC Pharmaceuticals,Inc (SHSE:600422)

We Think KPC PharmaceuticalsInc (SHSE:600422) Can Stay On Top Of Its Debt

KPC Pharmaceuticals,Inc, Annual General Meeting, Jun 21, 2024

Price target decreased by 7.1% to CN¥25.01

KPC Pharmaceuticals,Inc to Report Q1, 2024 Results on Apr 27, 2024

KPC PharmaceuticalsInc's (SHSE:600422) Profits May Not Reveal Underlying Issues

Full year 2023 earnings: EPS and revenues miss analyst expectations

KPC Pharmaceuticals,Inc to Report Fiscal Year 2023 Results on Mar 22, 2024

Third quarter 2023 earnings released

Investor sentiment improves as stock rises 16%

New minor risk - Earnings quality

Second quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.14 in 2Q 2022)

Investor sentiment deteriorates as stock falls 16%

Investor sentiment deteriorates as stock falls 16%

KPC Pharmaceuticals,Inc to Report First Half, 2023 Results on Aug 30, 2023

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 15%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.21 (vs CN¥0.13 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.18 in 2Q 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.17 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.18 (vs CN¥0.17 in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.26 (vs CN¥0.12 in 1Q 2020)

New Hope Healthcare Nanjing Investment Center (Limited Partnership) signed an agreement to acquire 3.7% stake in Nanjing Weili Zhibo Biotechnology Co., Ltd. from KPC Pharmaceuticals, Inc. (SHSE:600422) for CNY 30 million.

Full year 2020 earnings released: EPS CN¥0.60 (vs CN¥0.60 in FY 2019)

New 90-day low: CN¥8.34

KPC Pharmaceuticals, Inc. to Report Fiscal Year 2020 Results on Mar 16, 2021

New 90-day low: CN¥8.38

New 90-day low: CN¥9.12

New 90-day low: CN¥9.54

Third quarter earnings released

KPC Pharmaceuticals, Inc. to Report Q3, 2020 Results on Oct 22, 2020

A group of buyers agreed to acquire 51% stake in Kunming Yinnuo Pharmaceutical Technology Co., Ltd. from KPC Pharmaceuticals, Inc. (SHSE:600422) for approximately CNY 170 million.

KPC Pharmaceuticals, Inc. (SHSE:600422) cancelled the acquisition of 30% stake in Zhejiang Holley Nanhu Pharmaceutical Co., Ltd.

First half earnings released

New 90-day high - CN¥11.67

KPC Pharmaceuticals, Inc. to Report First Half, 2020 Results on Aug 21, 2020

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken